Short answer
Kimberly-Clark (KMB) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.05 (Costs Associated with Exit or Disposal Activities), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). K-C completed its acquisition of Kenvue, adding Kenvue’s consumer-health business to Kimberly-Clark’s portfolio.
Kimberly-Clark 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- K-C completed its acquisition of Kenvue, adding Kenvue’s consumer-health business to Kimberly-Clark’s portfolio
- Kenvue shareholders received 0.14625 K-C shares plus $3.50 cash per share
- Approximately 281,060,840 K-C shares issued or obligated, creating material equity dilution for existing shareholders
- Kenvue equity awards converted into K-C awards, with performance stock units becoming time-vesting restricted stock units
- Transaction completion shifts focus to integration execution, portfolio synergies and acquisition-related financial impacts
Item 2.05 · Costs Associated with Exit or Disposal Activities
- Kenvue Integration Program targets operating profit synergies by 2030, with actions underway through December 31, 2029
- Approximately $3.1 billion pre-tax charges, including $2.5 billion cash and $0.6 billion non-cash
- Cash costs concentrated in supply-chain optimization, ERP and technology integration, workforce reductions, and advisory services
- Additional approximately $1.4 billion capital spending required through December 31, 2029
- Material execution risk from restructuring complexity and potential costs beyond current estimates
Item 5.02 · Departure/Election of Directors or Officers
- Three former Kenvue directors joined K-C’s board, with planned shareholder nomination at the 2027 annual meeting
- Board turnover created vacancies for the Kenvue appointees, with no departures attributed to company disagreements
- One-time premium-priced options: $6.6M for CEO Michael Hsu, $2.15M for CFO Nelson Urdaneta, $1.8M for Jeffrey Melucci
- Exercise price set at the greater of $120 or 110% of K-C’s December 1, 2026 closing price, limiting immediate dilution incentives
- Awards vest fully December 1, 2029, aligning executives with Kenvue integration and long-term stock performance
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Amended bylaws effective November 2, 2026, upon completion of the Mergers
- Tighter advance-notice and disclosure rules for stockholder proposals and director nominations
- New Rule 14a-19 universal proxy compliance requirements, increasing procedural demands for dissident nominees
- Special-meeting procedures revised, potentially affecting stockholder ability to call meetings
- Exclusive federal forum for Securities Act claims, unless K-C consents to another venue
Item 7.01 · Regulation FD Disclosure
- K-C announced completion of the Mergers on November 2, 2026, marking a major corporate transaction milestone
- Integration of Kenvue now becomes the key execution focus, with potential synergies and cost savings dependent on successful integration
- Program-related charges and capital expenditures remain preliminary, creating potential earnings and cash-flow pressure
- Execution risks include higher integration costs, delayed implementation, operational disruption and unrealized volume increases
Item EX-99.1 · Exhibit EX-99.1
- Kenvue acquisition closed November 2, 2026, transforming KMB into a global consumer health and wellness platform
- Kenvue holders received $3.50 cash plus 0.14625 KMB shares per share, creating cash funding needs and shareholder dilution
- Management reaffirmed approximately $2.1B run-rate synergies: $1.9B cost savings and $500M revenue benefits, offset by $300M reinvestment
- Combined portfolio includes 10 billion-dollar brands across baby care, women’s health, active aging and consumer healthcare
- Kenvue shares stopped trading November 2, while three Kenvue directors joined KMB’s 13-member board
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kimberly-Clark 8-K filings
Get the next KMB 8-K as it lands
Follow KMB for push alerts, or ask the research agent what this filing means.